CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Summary

This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study will test whether new products called Chimeric Antigen Receptor T Cells (CAR T Cells), when given with chemotherapy, is safe and will reduce cPRA. The main study will last up to 2 years: Participants will have up to 30 clinic or hospital visits over a one-year period.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Kidney Transplant
• Kidney Failure
• End Stage Renal Failure on Dialysis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites